lenabasum and Gastritis

Ajulemic acid (CT-3, IP-751, 1',1'-dimethylheptyl-Delta8-tetrahydrocannabinol-11-oic acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic doses. In a variety of animal assays, AJA shows efficacy in models for pain and inflammation. Furthermore, in the rat adjuvant arthritis model, it displayed a remarkable action in preventing the destruction of inflamed joints. A phase-2 human trial with chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition. Its low toxicity, particularly its lack of ulcerogenicity, further suggests that it will have a highly favorable therapeutic index and may replace some of the current anti-inflammatory/analgesic medications. Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects.

Topics: Adult; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Experimental; Cannabinoids; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cytokines; Double-Blind Method; Dronabinol; Drug Evaluation, Preclinical; Edema; Female; Gastritis; Humans; Male; Mice; Middle Aged; Molecular Structure; Neuralgia; Randomized Controlled Trials as Topic; Rats